1. Roberts DJ, Field S, Delaney M, Bates I. Problems and approaches for blood transfusion in the developing countries. Hematol Oncol Clin North Am. 2016; 30 (2): 477-495. doi: 10.1016/j.hoc.2015.11.011.
2. Guerrero-Garcia JJ, Zuniga-Magana AG, Barrera-De Leon JC, Magana-Duarte R, Ortuno-Sahagun D. Retrospective study of the seroprevalence of HIV, HCV, and HBV in blood donors at a Blood Bank of Western Mexico. Pathogens. 2021;10 (7): 878. doi: 10.3390/pathogens10070878.
3. DOF. NORMA Oficial Mexicana NOM--253--SSA1--2012, Para la disposición de sangre humana y sus componentes con fines terapéuticos. DOF 26--10--2012. México: Diario Oficial de la Federación; 2012. p. 1-112.
4. FDA. Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components, including Source Plasma, to Reduce the Risk of Transmission.
5. FDA. Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV 1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry. Guidance for industry. In: U.S. Department of Health and Human Services FaDA, editor. United States of America. 2017. p. 1-42.